ATE435238T1 - Herstellung eines einkettigen fv antikörperfragments - Google Patents
Herstellung eines einkettigen fv antikörperfragmentsInfo
- Publication number
- ATE435238T1 ATE435238T1 AT04010702T AT04010702T ATE435238T1 AT E435238 T1 ATE435238 T1 AT E435238T1 AT 04010702 T AT04010702 T AT 04010702T AT 04010702 T AT04010702 T AT 04010702T AT E435238 T1 ATE435238 T1 AT E435238T1
- Authority
- AT
- Austria
- Prior art keywords
- preparation
- antibody fragment
- single chain
- methods
- antibody fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04010702A EP1593690B1 (de) | 2004-05-05 | 2004-05-05 | Herstellung eines einkettigen fv Antikörperfragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435238T1 true ATE435238T1 (de) | 2009-07-15 |
Family
ID=34924877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04010702T ATE435238T1 (de) | 2004-05-05 | 2004-05-05 | Herstellung eines einkettigen fv antikörperfragments |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8247194B2 (de) |
| EP (2) | EP1593690B1 (de) |
| AT (1) | ATE435238T1 (de) |
| AU (1) | AU2005238203B2 (de) |
| CA (1) | CA2562604C (de) |
| DE (1) | DE602004021773D1 (de) |
| DK (1) | DK1593690T3 (de) |
| WO (1) | WO2005105844A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE435238T1 (de) * | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| BRPI0608281B8 (pt) * | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| RU2447085C2 (ru) | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| US7741450B2 (en) | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| AU2013201228B2 (en) * | 2006-02-08 | 2016-01-21 | Eisai, Inc. | Antigenic gm-csf peptides and antibodies to gm-csf |
| JP5059119B2 (ja) | 2006-12-14 | 2012-10-24 | シェーリング コーポレイション | 操作された抗tslp抗体 |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| CN104072613A (zh) | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| CN102272158B (zh) * | 2008-11-12 | 2014-05-07 | 乔治·K·刘易斯 | 源自记忆b细胞的人单克隆抗体的快速表达克隆 |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| CN102271705A (zh) | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| ES2784123T3 (es) | 2009-11-04 | 2020-09-22 | Merck Sharp & Dohme | Anticuerpo anti TSLP genomodificado |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| WO2014068029A1 (en) | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| US12338458B2 (en) * | 2017-05-25 | 2025-06-24 | Memorial Sloan Kettering Cancer Center | Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| ATE435238T1 (de) * | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
-
2004
- 2004-05-05 AT AT04010702T patent/ATE435238T1/de active
- 2004-05-05 DE DE602004021773T patent/DE602004021773D1/de not_active Expired - Lifetime
- 2004-05-05 EP EP04010702A patent/EP1593690B1/de not_active Expired - Lifetime
- 2004-05-05 DK DK04010702T patent/DK1593690T3/da active
-
2005
- 2005-05-04 CA CA2562604A patent/CA2562604C/en not_active Expired - Lifetime
- 2005-05-04 US US11/568,685 patent/US8247194B2/en active Active
- 2005-05-04 WO PCT/EP2005/004893 patent/WO2005105844A2/en not_active Ceased
- 2005-05-04 AU AU2005238203A patent/AU2005238203B2/en not_active Expired
- 2005-05-04 EP EP05743231A patent/EP1742967A2/de not_active Withdrawn
-
2012
- 2012-08-17 US US13/588,678 patent/US9279017B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2562604A1 (en) | 2005-11-10 |
| AU2005238203B2 (en) | 2010-09-02 |
| DK1593690T3 (da) | 2009-11-09 |
| WO2005105844A3 (en) | 2006-01-26 |
| WO2005105844A2 (en) | 2005-11-10 |
| EP1593690B1 (de) | 2009-07-01 |
| US8247194B2 (en) | 2012-08-21 |
| US9279017B2 (en) | 2016-03-08 |
| EP1742967A2 (de) | 2007-01-17 |
| US20130171165A1 (en) | 2013-07-04 |
| DE602004021773D1 (de) | 2009-08-13 |
| US20080193978A1 (en) | 2008-08-14 |
| CA2562604C (en) | 2014-02-18 |
| AU2005238203A1 (en) | 2005-11-10 |
| EP1593690A1 (de) | 2005-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE435238T1 (de) | Herstellung eines einkettigen fv antikörperfragments | |
| LTPA2017038I1 (lt) | Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių | |
| WO2008097817A3 (en) | Multivariable antigens complexed with targeting humanized monoclonal antibody | |
| NO2017032I1 (no) | bezlotoksumab | |
| ATE452147T1 (de) | Antikörper mit korrigierten cdr | |
| WO2005069970A3 (en) | Antibody specificity transfer using minimal essential binding determinants | |
| WO2007137984A3 (en) | Modified humanised anti-interleukin-18 antibodies | |
| NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
| EP1912674B8 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
| CR20150102A (es) | Anticuerpos que se unen a il-4 y/o il-13 (divisional 2) | |
| NZ623706A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof | |
| IL197459A0 (en) | Humanized proteins, including antibodies and methods for producing the same | |
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| EA200901500A1 (ru) | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека | |
| IL202232A0 (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| WO2008027236A3 (en) | Multispecific antibodies | |
| WO2011117648A3 (en) | Disulfide stabilised antibodies and fragments thereof | |
| WO2006102200A3 (en) | Docetaxel immunoassay | |
| WO2008052108A3 (en) | Methods for use in human-adapting monoclonal antibodies | |
| MX2008002161A (es) | Anticuerpos quimericos con regiones de primate del nuevo mundo. | |
| NZ607881A (en) | Humanized antibody against amyloid beta | |
| WO2007049152A3 (en) | Methods of producing stable b-lymphocytes | |
| WO2008068359A8 (es) | Método para producir anticuerpos mediante inmunización con haptenos unidos a partículas de óxidos metálicos | |
| NZ708488A (en) | Method of providing disease-specific binding molecules and targets | |
| TH148531A (th) | วิธีการและองค์ประกอบสำหรับกำหนดเป้าหมายพอลิยูไบควิทิน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1593690 Country of ref document: EP |
|
| UEP | Publication of translation of european patent specification |
Ref document number: 1593690 Country of ref document: EP |